More information: Neither side wanted to participate in the Post Marketing Requirement ( PMR ) due to uncertainty of future sales. Meanwhile Perrigo, Teva and Prasco are carrying on the intellectual property of Axiron as generics, and might be found to owe money to Acrux after the coming legal ruling. Any PMR would assist them take advantage of Axiron, which is still owned by Acrux.
Add to My Watchlist
What is My Watchlist?
